Works matching IS 11732563 AND DT 2025 AND VI 45 AND IP 2
Results: 5
Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial: Altelyse Versus Actilyse: M. R. Beyranvand et al.
- Published in:
- Clinical Drug Investigation, 2025, v. 45, n. 2, p. 101, doi. 10.1007/s40261-025-01420-3
- By:
- Publication type:
- Article
Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine: Novel Extended-Release Ropivacaine Shows Consistent and Predictable PK: S. Pope et al
- Published in:
- Clinical Drug Investigation, 2025, v. 45, n. 2, p. 51, doi. 10.1007/s40261-025-01419-w
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity: Phase I RCT of S-309309 in Obesity: T. Ishibashi et al.
- Published in:
- Clinical Drug Investigation, 2025, v. 45, n. 2, p. 85, doi. 10.1007/s40261-024-01418-3
- By:
- Publication type:
- Article
Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints: Real World Safety of Using Icosapent Ethyl in Nationwide VHA Cohort: T. Patil et al
- Published in:
- Clinical Drug Investigation, 2025, v. 45, n. 2, p. 69, doi. 10.1007/s40261-024-01417-4
- By:
- Publication type:
- Article
The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2− Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered: Non-medication Expenses of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A. Pilehvari et al
- Published in:
- Clinical Drug Investigation, 2025, v. 45, n. 2, p. 59, doi. 10.1007/s40261-024-01416-5
- By:
- Publication type:
- Article